 |
9 Diseases |  |
1 Trial |
|
1 Trial |  |
50 News |  |
- | ASP7317 / Octapharma, Astellas
Trial completion date, Trial primary completion date: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (clinicaltrials.gov) - Nov 18, 2024
P1, N=42, Recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2026 --> Jun 2026
- ASP7317 / Octapharma, Astellas
Trial termination, Metastases: A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD (clinicaltrials.gov) - Feb 15, 2024
P1/2, N=10, Terminated, Sponsor: CHABiotech CO., Ltd
Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2026 --> Jun 2026 Unknown status --> Terminated; Sponsor decision
- || ASP7317 / Octapharma, Astellas
Trial completion: Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD) (clinicaltrials.gov) - Feb 7, 2024
P1, N=3, Completed, Sponsor: CHABiotech CO., Ltd
Unknown status --> Terminated; Sponsor decision Unknown status --> Completed
- || ASP7317 / Octapharma, Astellas
Phase classification, Enrollment change, Trial completion date, Trial primary completion date: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (clinicaltrials.gov) - Jan 2, 2024
P1, N=42, Recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Unknown status --> Completed Phase classification: P1b --> P1 | N=18 --> 42 | Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Dec 2025
- || ASP7317 / Octapharma, Astellas
Enrollment open, Trial completion date, Trial primary completion date: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (clinicaltrials.gov) - Aug 29, 2022
P1b, N=18, Recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Phase classification: P1b --> P1 | N=18 --> 42 | Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Dec 2025 Active, not recruiting --> Recruiting | Trial completion date: Nov 2022 --> Aug 2024 | Trial primary completion date: Nov 2022 --> Aug 2024
- || ASP7317 / Octapharma, Astellas
Enrollment change, Trial completion date, Trial primary completion date: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (clinicaltrials.gov) - Dec 10, 2020
P1b, N=18, Active, not recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Active, not recruiting --> Recruiting | Trial completion date: Nov 2022 --> Aug 2024 | Trial primary completion date: Nov 2022 --> Aug 2024 N=150 --> 18 | Trial completion date: Jan 2027 --> Nov 2022 | Trial primary completion date: Jan 2027 --> Nov 2022
- || ASP7317 / Octapharma, Astellas
Trial completion date, Trial primary completion date: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (clinicaltrials.gov) - Jun 25, 2020
P1b, N=150, Active, not recruiting, Sponsor: Astellas Institute for Regenerative Medicine
N=150 --> 18 | Trial completion date: Jan 2027 --> Nov 2022 | Trial primary completion date: Jan 2027 --> Nov 2022 Trial completion date: Oct 2026 --> Jan 2027 | Trial primary completion date: Apr 2021 --> Jan 2027
- || ASP7317 / Octapharma, Astellas
Enrollment closed: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (clinicaltrials.gov) - May 5, 2020
P1b, N=150, Active, not recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Trial completion date: Oct 2026 --> Jan 2027 | Trial primary completion date: Apr 2021 --> Jan 2027 Recruiting --> Active, not recruiting
- || ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Clinical, Journal: Subretinal transplantation of human embryonic stem cell-derived retinal pigment epithelium (MA09-hRPE): A safety and tolerability evaluation in minipigs. (Pubmed Central) - Feb 16, 2020
There were no other changes related to subretinal RPE cell injection. These results suggested that subretinal injection of hESC-derived RPE cells (60 and 120 × 10 cells/150 μL) in minipigs is well-tolerated and safe.
- | ASP7317 / Octapharma, Astellas
Trial completion date, Trial primary completion date, Metastases: A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD (clinicaltrials.gov) - Nov 18, 2019
P1/2, N=12, Active, not recruiting, Sponsor: CHABiotech CO., Ltd
These results suggested that subretinal injection of hESC-derived RPE cells (60 and 120 × 10 cells/150 μL) in minipigs is well-tolerated and safe. Trial completion date: Apr 2016 --> Jun 2020 | Trial primary completion date: Feb 2016 --> Jun 2020
- || ASP7317 / Octapharma, Astellas
Trial completion, Trial completion date, Trial primary completion date: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients (clinicaltrials.gov) - Nov 3, 2019
P1/2, N=13, Completed, Sponsor: Astellas Institute for Regenerative Medicine
Trial completion date: Apr 2016 --> Jun 2020 | Trial primary completion date: Feb 2016 --> Jun 2020 Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Jun 2019 | Trial primary completion date: Dec 2019 --> Jun 2019
- || ASP7317 / Octapharma, Astellas
Trial completion, Trial completion date, Trial primary completion date, Metastases: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD (clinicaltrials.gov) - Oct 30, 2019
P1/2, N=11, Completed, Sponsor: Astellas Institute for Regenerative Medicine
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Jun 2019 | Trial primary completion date: Dec 2019 --> Jun 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Jul 2019 | Trial primary completion date: Dec 2019 --> Jul 2019
- | ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Review, Journal: Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells (MA09-hRPE) in macular degeneration. (Pubmed Central) - Sep 5, 2019
Given that the technology is still at its infancy for human use, a new clinical regulatory path could aid in cell line validation through small cohort, adaptive clinical trials to accelerate product development toward commercialization. These strategic insights will be invaluable to help both academia and industry, collaboratively shorten the steep learning curve, and reduce large development expenditures spent on unnecessary lengthy clinical trials.
- | ASP7317 / Octapharma, Astellas
Enrollment open, Trial initiation date: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (clinicaltrials.gov) - Aug 1, 2018
P1b, N=150, Recruiting, Sponsor: Astellas Institute for Regenerative Medicine
These strategic insights will be invaluable to help both academia and industry, collaboratively shorten the steep learning curve, and reduce large development expenditures spent on unnecessary lengthy clinical trials. Not yet recruiting --> Recruiting | Initiation date: Dec 2018 --> Jul 2018
- || ASP7317 / Octapharma, Astellas
Trial initiation date: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (clinicaltrials.gov) - May 1, 2018
P1b, N=150, Not yet recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Not yet recruiting --> Recruiting | Initiation date: Dec 2018 --> Jul 2018 Initiation date: Mar 2018 --> Dec 2018
- || ASP7317 / Octapharma, Astellas
Trial initiation date, Trial primary completion date: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (clinicaltrials.gov) - Sep 21, 2017
P1b, N=150, Not yet recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Initiation date: Mar 2018 --> Dec 2018 Initiation date: Aug 2017 --> Mar 2018 | Trial primary completion date: Aug 2020 --> Apr 2021
- ASP7317 / Octapharma, Astellas
Trial withdrawal, Surgery: PORTRAY: Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD (clinicaltrials.gov) - Jul 26, 2017
P2, N=0, Withdrawn, Sponsor: Astellas Institute for Regenerative Medicine
Initiation date: Aug 2017 --> Mar 2018 | Trial primary completion date: Aug 2020 --> Apr 2021 Terminated --> Withdrawn
- ASP7317 / Octapharma, Astellas
Trial primary completion date, Metastases: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD (clinicaltrials.gov) - Jun 14, 2017
P1/2, N=11, Active, not recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Terminated --> Withdrawn Trial primary completion date: Aug 2029 --> Dec 2019
- ASP7317 / Octapharma, Astellas
Trial primary completion date: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients (clinicaltrials.gov) - Jun 14, 2017
P1/2, N=13, Active, not recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Trial primary completion date: Aug 2029 --> Dec 2019 Trial primary completion date: Aug 2029 --> Dec 2019
- ||| ASP7317 / Octapharma, Astellas
New P1 trial: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (clinicaltrials.gov) - Jun 5, 2017
P1b, N=150, Not yet recruiting, Sponsor: Astellas Institute for Regenerative Medicine
- ASP7317 / Octapharma, Astellas
Enrollment change, Trial termination, Surgery: PORTRAY: Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD (clinicaltrials.gov) - Jun 4, 2017
P2, N=8, Terminated, Sponsor: Astellas Institute for Regenerative Medicine
Trial primary completion date: Aug 2029 --> Dec 2019 N=60 --> 8 | Suspended --> Terminated; Changes to the study design and the cell line
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Enrollment change, Trial withdrawal, Trial primary completion date: Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=0, Withdrawn, Sponsor: University of California, Los Angeles
N=60 --> 8 | Suspended --> Terminated; Changes to the study design and the cell line N=12 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Jul 2016
- ASP7317 / Octapharma, Astellas
Trial completion, Enrollment change: Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) (clinicaltrials.gov) - Jun 10, 2016
P1/2, N=12, Completed, Sponsor: Astellas Institute for Regenerative Medicine
N=12 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Jul 2016 Active, not recruiting --> Completed | N=16 --> 12
- ASP7317 / Octapharma, Astellas
Trial completion, Trial primary completion date: Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy (clinicaltrials.gov) - Jun 10, 2016
P1/2, N=13, Completed, Sponsor: Astellas Institute for Regenerative Medicine
Active, not recruiting --> Completed | N=16 --> 12 Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Aug 2015
- ASP7317 / Octapharma, Astellas
Trial completion, Trial primary completion date, Metastases: Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (clinicaltrials.gov) - Jun 10, 2016
P1/2, N=13, Completed, Sponsor: Astellas Institute for Regenerative Medicine
Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Aug 2015 Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Aug 2015
- ASP7317 / Octapharma, Astellas
Trial suspension, Surgery: PORTRAY: Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD (clinicaltrials.gov) - Jun 9, 2016
P2, N=60, Suspended, Sponsor: Astellas Institute for Regenerative Medicine
Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Aug 2015 Recruiting --> Suspended
- ASP7317 / Octapharma, Astellas
Enrollment closed, Trial primary completion date, Metastases: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD (clinicaltrials.gov) - Jun 9, 2016
P1/2, N=11, Active, not recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Recruiting --> Suspended Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2029 --> Aug 2029
- ASP7317 / Octapharma, Astellas
Enrollment closed, Trial primary completion date: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients (clinicaltrials.gov) - Jun 9, 2016
P1/2, N=12, Active, not recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2029 --> Aug 2029 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2029 --> Aug 2029
- | ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Enrollment open, Trial primary completion date: Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration (clinicaltrials.gov) - Feb 8, 2016
P1/2, N=12, Recruiting, Sponsor: University of California, Los Angeles
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2029 --> Aug 2029 Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2015 --> Dec 2017
- ASP7317 / Octapharma, Astellas
Trial primary completion date: Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=16, Active, not recruiting, Sponsor: Ocata Therapeutics
Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2015 --> Dec 2017 Trial primary completion date: Aug 2015 --> Aug 2014
- ASP7317 / Octapharma, Astellas
Trial primary completion date, Metastases: Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=16, Active, not recruiting, Sponsor: Ocata Therapeutics
Trial primary completion date: Aug 2015 --> Aug 2014 Trial primary completion date: Aug 2015 --> Aug 2014
- ||||| ASP7317 / Octapharma, Astellas
New P2 trial, Surgery: PORTRAY: Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD (clinicaltrials.gov) - Sep 30, 2015
P2, N=60, Recruiting, Sponsor: Ocata Therapeutics
- ASP7317 / Octapharma, Astellas
New P1/2 trial, Metastases: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD (clinicaltrials.gov) - Jun 4, 2015
P1/2, N=13, Enrolling by invitation, Sponsor: Ocata Therapeutics
- ASP7317 / Octapharma, Astellas
New P1/2 trial: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients (clinicaltrials.gov) - May 15, 2015
P1/2, N=13, Enrolling by invitation, Sponsor: Ocata Therapeutics
- ASP7317 / Octapharma, Astellas
Enrollment closed, Trial primary completion date: Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy (clinicaltrials.gov) - Apr 28, 2015
P1/2, N=16, Active, not recruiting, Sponsor: Ocata Therapeutics
Trial primary completion date: Aug 2015 --> Aug 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Aug 2015
- ASP7317 / Octapharma, Astellas
Enrollment closed, Trial primary completion date, Metastases: Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (clinicaltrials.gov) - Apr 28, 2015
P1/2, N=16, Active, not recruiting, Sponsor: Ocata Therapeutics
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Aug 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Aug 2015
- ASP7317 / Octapharma, Astellas
Enrollment closed, Trial primary completion date: Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD) (clinicaltrials.gov) - Feb 19, 2015
P1, N=3, Active, not recruiting, Sponsor: CHABiotech CO., Ltd
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Aug 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Mar 2015
- ASP7317 / Octapharma, Astellas
Enrollment closed, Trial primary completion date: Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) (clinicaltrials.gov) - Feb 9, 2015
P1/2, N=16, Active, not recruiting, Sponsor: Ocata Therapeutics
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Mar 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Oct 2015
- ASP7317 / Octapharma, Astellas
Trial primary completion date: Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy (clinicaltrials.gov) - Nov 4, 2014
P1/2, N=16, Recruiting, Sponsor: Advanced Cell Technology
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Oct 2015 Trial primary completion date: Aug 2014 --> Nov 2014
- ASP7317 / Octapharma, Astellas
Trial primary completion date, Metastases: Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (clinicaltrials.gov) - Nov 4, 2014
P1/2, N=16, Recruiting, Sponsor: Advanced Cell Technology
Trial primary completion date: Aug 2014 --> Nov 2014 Trial primary completion date: Aug 2014 --> Nov 2014
- ASP7317 / Octapharma, Astellas
Trial primary completion date: Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) (clinicaltrials.gov) - Sep 22, 2014
P1/2, N=16, Recruiting, Sponsor: Advanced Cell Technology
Trial primary completion date: Aug 2014 --> Nov 2014 Trial primary completion date: Jul 2014 --> Nov 2014
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
New P1/2 trial: Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration (clinicaltrials.gov) - Apr 22, 2014
P1/2, N=0, Not yet recruiting, Sponsor: University of California, Los Angeles
- | ASP7317 / Octapharma, Astellas
Enrollment change: Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) (clinicaltrials.gov) - Jan 28, 2013
P1/2, N=16, Recruiting, Sponsor: Advanced Cell Technology
Trial primary completion date: Jul 2014 --> Nov 2014 N=12 --> 16
- | ASP7317 / Octapharma, Astellas
Enrollment change: Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy (clinicaltrials.gov) - Jan 28, 2013
P1/2, N=16, Recruiting, Sponsor: Advanced Cell Technology
N=12 --> 16 N=12 --> 16
- | ASP7317 / Octapharma, Astellas
Enrollment change, Metastases: Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (clinicaltrials.gov) - Jan 28, 2013
P1/2, N=16, Recruiting, Sponsor: Advanced Cell Technology
N=12 --> 16 N=12 --> 16
- | ASP7317 / Octapharma, Astellas
Enrollment open, Metastases: A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD (clinicaltrials.gov) - Oct 21, 2012
P1/2, N=12, Recruiting, Sponsor: CHA Bio & Diostech
N=12 --> 16 Not yet recruiting --> Recruiting
- ASP7317 / Octapharma, Astellas
Enrollment open: Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD) (clinicaltrials.gov) - Oct 21, 2012
P1, N=3, Recruiting, Sponsor: CHA Bio & Diostech
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | ASP7317 / Octapharma, Astellas
New P1/2 trial, Metastases: A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD (clinicaltrials.gov) - Aug 27, 2012
P1/2, N=12, Recruiting, Sponsor: CHA Bio & Diostech
- ASP7317 / Octapharma, Astellas
New P1 trial: Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD) (clinicaltrials.gov) - Jun 19, 2012
P1, N=3, Recruiting, Sponsor: CHA Bio & Diostech
- | ASP7317 / Octapharma, Astellas
New P1/2 trial: Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) (clinicaltrials.gov) - Nov 8, 2011
P1/2, N=16, Recruiting, Sponsor: Advanced Cell Technology